Advanced Cell Technology to Present at Regenenerative Medicine Investor Day March 26, 2014
March 21 2014 - 4:00PM
Business Wire
Advanced Cell Technology (ACTC) today announced that Edward
Myles, Interim President, CFO & EVP of Corporate Development,
will present at the 2nd Annual Regen Med Investor Day to be held
Wednesday, March 26, 2014 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in
partnership with leading financial firms Maxim Group and Piper
Jaffray, this one-day investor conference focuses exclusively on
the regenerative medicine and advanced therapies sector. The event
includes clinical and commercial experts who will be on-hand to
address specific questions regarding the outlook for the industry,
as well as offer insight into how regenerative medicine products
could impact the standard of care in key therapeutic areas. The
program will include talks by key opinion leaders in the industry,
life science investment experts and analysts as well as
presentations by more than 30 leading companies from across the
globe.
The following are specific details regarding Advanced Cell
Technology’s presentation:
Event:
ARM’s Regen Med Investor Day
Date: March 26, 2014 Time: 4:30 Eastern Location: Metropolitan
Club, One East 60th Street, New York, NY 10022
A live-streaming webcast of all panels and company presentations
will be available at: http://www.arminvestorday.com/webcast and
will be published on the event’s website shortly after the
conference.
Attendance at this event is for credentialed investors and
members of the media only. If you are interested in attending,
please contact Laura Parsons at lparsons@alliancerm.org. Please
visit http://www.arminvestorday.com for more information.
About Advanced Cell Technology:
Advanced Cell Technology, Inc. is a Marlborough, Mass.-based
biotechnology company focused on the development and
commercialization of human embryonic stem cell (hESC) and adult
stem cell technology. The company’s most advanced products are in
clinical trials for the treatment of dry age-related macular
degeneration and Stargardt’s macular degeneration. ACT’s
preclinical programs involve cell therapies for the treatment of
other ocular disorders and for diseases outside the field of
ophthalmology, including autoimmune, inflammatory and wound
healing-related disorders. The company’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information,
http://www.advancedcell.com or connect with the Company on
Facebook, Twitter, LinkedIn, Google+, and YouTube.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington,
DC-based multi-stakeholder advocacy organization that promotes
legislative, regulatory and reimbursement initiatives necessary to
facilitate access to life-giving advances in regenerative medicine
and advanced therapies. ARM also works to increase public
understanding of the field and its potential to transform human
healthcare, providing business development and investor outreach
services to support the growth of its member companies and research
organizations. Prior to the formation of ARM in 2009, there was no
advocacy organization operating in Washington, DC to specifically
represent the interests of the companies, research institutions,
investors and patient groups that comprise the entire regenerative
medicine community. Today ARM has more than 150 members and is the
leading global advocacy organization in this field. To learn more
about ARM or to become a member, visit www.alliancerm.org.
Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo
PartnersDavid Schull, 858-717-2310